MedPharm Team

Michael Kane is the Chief Executive Officer of MedPharm, Ltd. Mr. Kane’s career includes over 20 years of experience in leading pharmaceutical and health & wellness businesses across Rx, generic OTC, and infant formula regulatory segments in CEO, COO, and other senior operating roles. This experience spanned topical, soft gel, tablet, powder, and liquid dosage forms. Most recently, he was the COO at the International Vitamin Corporation. Previous to that Mr. Kane was an Operating Partner with Blue Point Capital Partners, and CEO of a topical CDMO focused in Rx, Generic, OTC, and Dx Dispensed products. Prior to his involvement with privately held enterprises, he held a series of progressive leadership roles with Novartis and Abbott Laboratories and has worked with such leading brands as Similac®, Ensure®, Gerber®, Selsun Blue® and Murine®/Clear Eyes®. Mr. Kane currently serves as an Advisor for the University of Notre Dame’s Mendoza School of Business MBA program. Mr. Kane earned his MBA from the University of Notre Dame and a Bachelor of Science in Business Management from Indiana University of Pennsylvania. He also served as a Captain in the United States Marine Corps. 

Peter Geiger is the Chief Financial Officer at MedPharm, Ltd. Peter brings with him a depth of expertise in providing financial and operational leadership to a diverse portfolio of companies from start-ups to a $240M-pharmaceutical contract manufacturing organization. His leadership experience encompasses guiding companies through venture capital funding, mergers, acquisitions, and day-to-day operational strategic management for U.S. and international markets. His career is steeped in medicine and pharmaceuticals, including time spent as a neurochemistry research analyst for the National Institutes of Health’s National Institute of Neurological Disorders and Stroke(NINDS). Before joining MedPharm, Peter served as COO and CFO for Perfusio, was VP of Finance at DSM where he led the financial integration of the CDMO business into Patheon following the merger of the two. He earned his MBA from The Wharton School of the University of Pennsylvania and a Bachelor of Science in Behavioral Neuroscience from Lehigh University. 

Jon Lenn has direct responsibility for MedPharm’s operations in the United States based out of Durham, North Carolina. Since joining in 2015 he has led MedPharm’s development of cutting edge performance models for assessing penetration and activity of clients’ products targeted towards key biochemical pathways. He has over 15 years’ experience in developing dermatological projects with Connetics, Stiefel and GSK and has been directly involved with the development and approval of 8 products. He received his PhD on the topical delivery of macromolecules from the University of Reading.

Charles Evans has been with MedPharm for over 15 years and has been heavily involved in evolving and refining the company’s rigorous approach to formulation development. Charles has many years of expertise in the successful development of robust commercial products across all types of topical, inhalation and transdermal formulations. Moreover, he played a key role in the development of MedPharm’s proprietary MedSpray® technology that is currently under license to customers to enhance their products’ performance. He obtained his PhD at the University of Hertfordshire for the development of a novel dynamic spray formulation for the treatment of Athlete’s foot.

Naomi Seresinhe is the Senior Vice President, Business Operations at MedPharm, Ltd. She has over 20 years of operational experience in the biotechnology, banking and auto manufacturing industries. She brings a proven ability to lead strategic and tactical cross-functional initiatives including operational centers, customer service, financial reporting, and inventory control. Naomi plays a critical role in helping MedPharm identify and implement opportunities to improve operational performance and customer experiences. Before joining MedPharm, she spent over a decade in roles of increasing responsibility at Cytovance Biologics where she ultimately led the Marketing, Business Development and Program Management Teams, and negotiated several customer MSAs and strategic partnership deals with industry leaders. She earned her MBA from City University of Seattle and a Bachelor of Science in Microbiology from the University of Saskatchewan.

Marta joined MedPharm as Vice President of Quality Assurance in 2020. She brings with her over thirty years of diverse process and product experience in the biotech and pharmaceutical industry working in manufacturing, QC, Validation and QA areas. She has held leadership roles for companies like Cambrex, Abbott, MedImmune, DPT and most recently Torrent Pharma. Marta will be responsible for advancing the Quality Systems in the US for GLP and cGMP operations. Marta has a B.S in Chemical Engineering from the University of Puerto Rico, Mayaguez.

Melanie Gubeno joined MedPharm in July 2021 as our Senior Director of Human Resources. With over 20 years of experience, she has served in a variety of HR positions and joins MedPharm after leading HR teams with increasing responsibility at Harland Clarke Corporation, and most recently at Ontic. Melanie plays a critical role in maturing our employee management systems and benefit programs to offer a best-in-class approach and rewards package. Melanie has a Bachelor of Arts in Business Administration from Ashland University (Summa Cum Laude), an MBA from Capital University and the following HR accreditations (SPHR and SHRM-SCP).

Daniel Morland started at MedPharm in 2018 as a Senior Business Development Manager and returned in 2024 as Senior Director of Sales & Marketing. He brings with him more than 15 years of experience in the pharmaceutical industry, with an emphasis on contract services. Prior to joining MedPharm, Daniel worked in sales and management roles at organizations such as Reading Scientific Services, Butterworth Laboratories, and Simbec-Orion. He holds an MBA from the University of Warwick Business School.

John Dixon joined Tergus Pharma in 2023 and now serves as MedPharm’s Director of Manufacturing Operations. He has more than 25 years of experience with analytical research and development, GMP manufacturing operations, and commercial production within the life sciences and pharmaceutical industry. Prior to joining MedPharm, John has worked at pharmaceutical and contract service organizations such as Pfizer, Novo Nordisk, Fujifilm Diosynth, Merck, and KBI BioPharma. John has a Bachelor of Science in Biology from North Carolina Agricultural and Technical State University. John is also a retired Chief Warrant Officer in the United States Army Reserve. 

Patrick joined Ampersand as an Operating Partner in 2018 and has been CEO of three Ampersand portfolio companies including Alcami, TriPharm Services and Avista Pharma. He currently serves as Chairman of the Board of Alcami and Chairman of the Board of ANI Pharmaceuticals. He has been involved in other Ampersand portfolio companies, serving as Chairman of Brammer Bio and a Director at MedPharm, Ltd. He has extensive experience directing pharmaceutical manufacturing and lab operations on a global scale in fill finish, API, specialty pharmaceutical, formulation, manufacturing, and analytical contract development organizations. Over the course of his 42-year career in the healthcare industry, Patrick has been CEO of six pharma companies and served as a company director in fifteen healthcare organizations.

David Parker is a General Partner of Ampersand Capital Partners, which he joined in 1994. Prior to Ampersand, David was a management consultant at Bain & Company and Mercer Consulting, and a corporate lender at First National Bank of Boston. Mr. Parker currently serves on the Boards of Directors of Bioventus, Detector Technologies, Gyros Protein Technologies and MedPharm. His prior Board Directorships have included Avista Pharma, ACLARA Biosciences, Assay Designs, NOVEX, Roadrunner Pharmacy and Signature Genomic Laboratories. David currently heads Ampersand’s European office, which is based in Amsterdam.

Trevor Wahlbrink is a Partner of Ampersand Capital Partners, which he joined in 2012. Prior to Ampersand, Mr. Wahlbrink was an investment banker at Morgan Keegan and Covington Associates where he advised on merger and acquisition and capital raising transactions for middle market healthcare and technology companies. Mr. Wahlbrink currently serves on the Boards of Directors of Confluent Medical and MedPharm. His prior Board Directorships have included Avista Pharma, Corpus Medical, Elite One Source Nutritional Services and ETE Medical. Mr. Wahlbrink is based in Ampersand’s Wellesley, MA USA offices.

Minor Hinson is a Senior Managing Director and the Chief Investment Officer of Bourne Partners Strategic Capital (“BPSC”). Over the course of his career, Minor has been involved in financial transactions totaling over $10 billion, including venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market) and other corporate finance advisory assignments. Minor has also served on the Board of Directors for a number of companies over his career. Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill.